For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for Alzheimer’s Disease (AD) and other dementias. Despite extensive research, the fundamental mechanisms behind these neurodegenerative diseases are still not fully understood, and effective management of AD is taking longer than expected.
EMA committee rethinks stance and recommends Leqembi for Alzheimer’s disease – Pharmaceutical Technology
The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi (lecanemab) as a treatment for Alzheimer’s
November 14, 2024